Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ropivacaine + dexmedetomidine is a combination of two drugs used primarily for regional anesthesia and postoperative analgesia. Ropivacaine is an amide-type local anesthetic that blocks nerve impulse transmission by inhibiting sodium channels, resulting in loss of sensation and pain relief. Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist that acts as an adjuvant to local anesthetics, providing sedative, anxiolytic, and analgesic effects without significant respiratory depression. When combined, dexmedetomidine enhances the efficacy of ropivacaine by prolonging the duration of sensory and motor blockades, reducing postoperative pain scores, decreasing opioid consumption, and lowering the incidence of adverse effects such as nausea and vomiting compared to ropivacaine alone[1][5][6]. This combination has been studied across various surgical procedures (e.g., epidural anesthesia for cesarean section or lumbar spine surgery) in both adult and pediatric populations[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ropivacaine + dexmedetomidine.